Skip to main content
. 2017 Jul 10;36(16):2373–2389. doi: 10.15252/embj.201694912

Figure 7. Reduced Ccn1 levels in endothelial cells inhibit cancer cell transendothelial migration.

Figure 7

  1. Silencing CCN1 in a monolayer of HUVECs inhibits the capability of PC3 cells to invade the endothelial monolayer, as measured by reduced number of PC3 cells that invaded the monolayer after 24 h of co‐culture (left), and reduced amount of disrupted regions of the monolayer (right). siCTL n = 21, siCCN1 n = 23 fields assessed from one representative experiment of two.
  2. Representative immunofluorescence staining of (A). Red = VE‐cadherin (CDH5, HUVECs); green = fluorescently labeled PC3 cells. Scale bar = 100 μm.
  3. Transendothelial migration assay performed with PC3 cells (clone TEM4‐18) and HMVECs on transwells showing that silencing of CCN1 in HMVECs reduces the passage of cancer cells through the endothelial monolayer. N = 20 (siCTL), 9 (siCCN1 pool) and 10 (siCCN1 #1) fields assessed from two independent experiments.
  4. Representative immunofluorescence staining of (C). Red = VE‐cadherin (CDH5, HUVECs); green = fluorescently labeled PC3 cells. Scale bar = 20 μm.
  5. Working model for CCN1 in the tumor vasculature.
Data information: Bars represent mean ± SEM. Significance based on two‐tailed unpaired t‐test.